METABOLIK SINDROMDA BUYRAK YETISHMOVCHILIGINING PROGNOSTIK KLINIK MARKERLARI
##article.subject##:
buyrak yetishmovchiligi, metabolik sindrom, semizlik, biomarkerlar, metabolomika.##article.abstract##
Vazn ortishining yuqori darajada tarqalishi jiddiy tibbiy va ijtimoiy muammodir. So'nggi tadqiqotlar shuni ko'rsatdiki, metabolik sindromning rivojlanish xavfi yog' massasining hajmi bilan emas, balki uning gormonal va metabolik faolligi bilan bog'liq bo'lib, bu metabolik salomatlik tushunchasini semizlikning zamonaviy tasnifi shakllantirish uchun asos bo'lib xizmat qilgan. Biroq, uning fenotiplarining ta'riflari munozarali bo'lib qolmoqda. Semizlik, shuningdek, surunkali buyrak kasalligi (SBYe) rivojlanishining muhim xavf omillaridan biri hisoblanadi, shu bilan birga, turli xil semirish fenotiplarining buyrak kasalliklarining rivojlanishiga qo'shgan hissasi bo'yicha konsensus mavjud emas. Bir qancha tadqiqotlar metabolik sindromi bo'lgan bemorlarda buyrak disfunktsiyasini aniqlash uchun erta buyrak shikastlanishining belgilaridan foydalanish imkoniyatini isbotladi. Preklinik buyrak shikastlanishining belgilari va semizlikning gormonal va metabolik komponentini tavsiflovchi parametrlar o'rtasidagi bog'liqlik haqida ma'lumotlar kam. Epidemiologik tadqiqotlar semizlik bor bemorlarda SBYe kombinatsiyasining yuqori tarqalishini ko'rsatdi. Semizlikning turli fenotiplarining buyraklar buzilishining shakllanishiga qo'shgan hissasini aniqlashga qaratilgan tadqiqotlar asosan Osiyo aholisida o'tkazildi. Preklinik buyrak disfunktsiyasining rivojlanishida metabolik jihatdan sog'lom semizlik fenotipining roli haqida ma'lumot yo'q. Semizlik rivojlanishiga genetik moyillikni aniqlash zamonaviy tibbiyotning istiqbolli yo'nalishi hisoblanadi.
Библиографические ссылки
Современные принципы диагностики и лечения хронической болезни почек: методическое руководство для врачей / М.Ю. Швецов [и др.] // под.ред. Е.М. Шилова. Саратов. – 2017. – С. 123-148.
Ташкенбаева Э.Н. Гиперурикемия в патогенезе, клинике метаболического синдрома и развитие сердечно- сосудистых осложнений// Диссертация-2010-Ташкент-216с.
Ташкенбаева Э.Н., Атаева М.С., Кадырова Ф.Ш., Тогаев Д.Х.- Значение уровня мочевой кислоты в клинике и патогенезе острого коронарного синдрома// Проблемы и биологии и медицины- Научный журнал по теоретическим и практическим проблемам биологии и медицины- 2017, №3(96) С.104-106
Ташкенбаева Э.Н., Абдиева Г.А., Зугуров И.Х., Кадырова Ф.Ш Влияние гиперурикемии на клиническое течение и развитие осложнений ИБС/ Наука и образование: проблемы и стратегии развития. Материалы III международной научно-практической конференции 15-16 ноября 2017 г. Уфа С.34-37
Ташкенбаева Э.Н., Аляви А.Л., Тагаев Д.Х. Бессимптомная гиперурикемия: Патогенетические аспекты, клиника, прогнозирование и коррекция// Издательство «Фан» Академии наук Республики Узбекистан, Ташкент 2014.-С34-53.
Ташкенбаева Э.Н., Хайдарова Д.Д., Хасанжанова Ф.О., Абдиева Г., Усмонов Х.- Влияние эндотелиальной дисфункции и наиболее неблагоприятные факторы риска на развитие нестабильной стенокардии// Материалы ХХII международной научно - практической интернет - конференции «Тенденции и перспективы развития науки и образования в условиях глобализации». Переяслав-Хмельницкий. 28 февраля 2017 года. С. 501-503.
Томилина Н.А. Эпидемиология хронической почечной недостаточности и новые подходы к классификации и оценке тяжести хронических прогрессирующих заболеваний почек / Н.А. Томилина, Б.Т. Бикбов // Тер.архив. – 2015. - № 6. – С. 87-92.
Фомин В.В. Хроническая болезнь почек / В.В. Фомин. - М.: ГЭОТАР-Медиа, 2017. - 599-600 с.
Функциональное состояние почек и прогнозирование сердечнососудистого риска/А.О.Базаров. - М.,- 2017.- 557–584 с.
Шутов А.М. Хроническая болезнь почек - глобальная проблема XXI века / А.М. Шутов // Клиническая медицина. - 2017. - №5. – С. 5-10.
ADVANCE Collaborative GroupPatel A, MacMahon S et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2018; 358: 2560–2572
Agarwal R, Duffin KL, Laska DAet al. A prospective study of multiple protein biomarkers to predict progression in diabetic chronic kidney disease. Nephrol Dial Transplant 2014; 29: 2293–2302
Andersen S, Mischak H, Zurbig P et al. Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria. BMC Nephrol 2010; 11: 29 100. Lambers Heerspink HJ, de Zeeuw D, Sharma S et al. Urine metabolomic profile correlates with renal function and changes during atrasentan therapy in patients with diabetes and nephropathy [abstract]. J Am Soc Nephrol 2014; 25: 546A
Apperloo AJ, de Zeeuw D, de Jong PE. A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function. Kidney Int 2017; 51: 793–797
Ben Ameur R, Molina L, Bolvin C et al. Proteomic approaches for discovering biomarkers of diabetic nephropathy. Nephrol Dial Transplant 2020; 25: 2866–2875
Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2021; 345: 861–869
Chaiken RL, Eckert-Norton M, Bard M et al. Hyperfiltration in African-American patients with type 2 diabetes. Cross-sectional and longitudinal data. Diabetes Care 2018; 21: 2129–2134
Cho EH, Kim MR, Kim HJ et al. The discovery of biomarkers for type 2 diabetic nephropathy by serum proteome analysis. Proteomics Clin Appl 2017; 1: 352–361
DCCT/EDIC Research Groupde Boer IH, Sun W et al. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med 2021; 365: 2366–2376
Desai AS, Toto R, Jarolim P et al. Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD. Am J Kidney Dis 2019; 58: 717–728
Fechete R, Heinzel A, Perco P et al. Mapping of molecular pathways, biomarkers and drug targets for diabetic nephropathy. Proteomics Clin Appl 2018; 5: 354–366
Fioretto P, Stehouwer CD, Mauer M et al. Heterogeneous nature of microalbuminuria in NIDDM: studies of endothelial function and renal structure. Diabetologia 2018; 41: 233–236
Gerszten RE, Wang TJ. The search for new cardiovascular biomarkers. Nature 2018; 451: 949–952
Gnudi L, Viberti G, Raij L et al. GLUT-1 overexpression: link between hemodynamic and metabolic factors in glomerular injury? Hypertension 2020; 42: 19–24
Gohda T, Niewczas MA, Ficociello LH et al. Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetes. J Am Soc Nephrol 2021; 23: 516–524
Good DM, Zurbig P, Argiles A et al. Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics 2020; 9: 2424–2437
Haller H, Ito S, Izzo JL, Jr et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2021; 364: 907–917
Han LD, Xia JF, Liang QL et al. Plasma esterified and non-esterified fatty acids metabolic profiling using gas chromatography-mass spectrometry and its application in the study of diabetic mellitus and diabetic nephropathy. Anal Chim Acta 2021; 689: 85–91
Hellemons ME, Persson F, Bakker SJ et al. Initial angiotensin receptor blockade-induced decrease in albuminuria is associated with long-term renal outcome in type 2 diabetic patients with microalbuminuria: a post hoc analysis of the IRMA-2 trial. Diabetes Care 2019; 34: 2078–2083
Holtkamp FA, de Zeeuw D, Thomas MC et al. An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int 2019; 80: 282–287
Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2021; 345: 851–860
Lorenzo V, Saracho R, Zamora J et al. Similar renal decline in diabetic and non-diabetic patients with comparable levels of albuminuria. Nephrol Dial Transplant 2020; 25: 835–841
Magee GM, Bilous RW, Cardwell CR et al. Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis. Diabetologia 2019; 52: 691–697
Merchant ML, Perkins BA, Boratyn GM et al. Urinary peptidome may predict renal function decline in type 1 diabetes and microalbuminuria. J Am Soc Nephrol 2019; 20: 2065–2074
Miao Y, Ottenbros SA, Laverman GD et al. Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial. Hypertension 2018; 58: 2–7
Mohanram A, Zhang Z, Shahinfar S et al. The effect of losartan on hemoglobin concentration and renal outcome in diabetic nephropathy of type 2 diabetes. Kidney Int 2018; 73: 630–636
Morton J, Zoungas S, Li Q et al. Low HDL cholesterol and the risk of diabetic nephropathy and retinopathy: results of the ADVANCE study. Diabetes Care 2018; 35: 2201–2206
Parving HH, Andersen AR, Smidt UM et al. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 2021; 1: 1175–1179
Shurraw S, Hemmelgarn B, Lin M et al. Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: a population-based cohort study. Arch Intern Med 2019; 171: 1920–1927
Tam FW, Riser BL, Meeran K et al. Urinary monocyte chemoattractant protein-1 (MCP-1) and connective tissue growth factor (CCN2) as prognostic markers for progression of diabetic nephropathy. Cytokine 2019; 47: 37–42
Titan SM, Zatz R, Graciolli FG et al. FGF-23 as a predictor of renal outcome in diabetic nephropathy. Clin J Am Soc Nephrol 2018; 6: 241–247
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 2018; 352: 837–853
